These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 32930141

  • 1. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
    Kaira K, Naruse I, Shimizu K, Asao T.
    J Cancer Res Ther; 2020; 16(4):919-921. PubMed ID: 32930141
    [Abstract] [Full Text] [Related]

  • 2. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
    Yamamoto Y, Okamoto I, Otsubo K, Iwama E, Hamada N, Harada T, Takayama K, Nakanishi Y.
    Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
    [Abstract] [Full Text] [Related]

  • 3. Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease.
    Nitawaki T, Sakata Y, Kawamura K, Ichikado K.
    BMC Pulm Med; 2017 Dec 06; 17(1):173. PubMed ID: 29207989
    [Abstract] [Full Text] [Related]

  • 4. Successful treatment with alectinib after crizotinib-induced interstitial lung disease.
    Chino H, Sekine A, Kitamura H, Kato T, Ogura T.
    Lung Cancer; 2015 Dec 06; 90(3):610-3. PubMed ID: 26452431
    [Abstract] [Full Text] [Related]

  • 5. Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma.
    Gadotti LL, Nogueira Amorim Canedo FS, Ribeiro MFSA, Sacardo KP, Saddi R, Machado Alessi JV, de Abreu Testagrossa L, Katz A.
    Clin Lung Cancer; 2021 May 06; 22(3):e481-e486. PubMed ID: 32771343
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
    Bedas A, Peled N, Maimon Rabinovich N, Mishaeli M, Shochat T, Zer A, Rotem O, Allen AM, Bar J, Dudnik E, On behalf of the Israel Lung Cancer Group.
    Oncol Res Treat; 2019 May 06; 42(5):275-282. PubMed ID: 30955009
    [Abstract] [Full Text] [Related]

  • 7. Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease.
    Huang JR, Chou CW, Chao HS.
    J Oncol Pharm Pract; 2021 Jul 06; 27(5):1311-1314. PubMed ID: 33054691
    [Abstract] [Full Text] [Related]

  • 8. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
    Hu S, Li Q, Peng W, Feng C, Zhang S, Li C.
    J Thorac Oncol; 2018 May 06; 13(5):e72-e74. PubMed ID: 29703539
    [No Abstract] [Full Text] [Related]

  • 9. Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
    Ikeda S, Yoshioka H, Arita M, Sakai T, Sone N, Nishiyama A, Niwa T, Hotta M, Tanaka T, Ishida T.
    Jpn J Clin Oncol; 2015 Feb 06; 45(2):221-4. PubMed ID: 25398579
    [Abstract] [Full Text] [Related]

  • 10. Successful re-introduction of alectinib after inducing interstitial lung disease in a patient with lung cancer.
    Hwang A, Iskandar A, Dasanu CA.
    J Oncol Pharm Pract; 2019 Sep 06; 25(6):1531-1533. PubMed ID: 30572795
    [Abstract] [Full Text] [Related]

  • 11. Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.
    Masuda N, Ohe Y, Gemma A, Kusumoto M, Yamada I, Ishii T, Yamamoto N.
    Cancer Sci; 2019 Apr 06; 110(4):1401-1407. PubMed ID: 30776174
    [Abstract] [Full Text] [Related]

  • 12. Successful alectinib desensitization in a patient with anaplastic lymphoma kinase-positive adenocarcinoma of the lung and alectinib-induced drug rash.
    Anderson BE, Luczak TS, Ries LM, Hoefs GE, Silva-Benedict AC.
    J Oncol Pharm Pract; 2020 Dec 06; 26(8):2028-2030. PubMed ID: 32476587
    [Abstract] [Full Text] [Related]

  • 13. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, ALEX Trial Investigators.
    N Engl J Med; 2017 Aug 31; 377(9):829-838. PubMed ID: 28586279
    [Abstract] [Full Text] [Related]

  • 14. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
    Shirasawa M, Kubotaa M, Harada S, Niwa H, Kusuhara S, Kasajima M, Hiyoshi Y, Ishihara M, Igawa S, Masuda N.
    Lung Cancer; 2016 Sep 31; 99():66-8. PubMed ID: 27565916
    [Abstract] [Full Text] [Related]

  • 15. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
    Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L.
    Lancet Respir Med; 2019 May 31; 7(5):437-446. PubMed ID: 30981696
    [Abstract] [Full Text] [Related]

  • 16. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T.
    Lancet; 2017 Jul 01; 390(10089):29-39. PubMed ID: 28501140
    [Abstract] [Full Text] [Related]

  • 17. Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib.
    Zhang Y, Qin Y, Xu H, Yao Q, Gao Y, Feng Y, Ren J.
    Pathol Oncol Res; 2021 Jul 01; 27():637745. PubMed ID: 34257603
    [Abstract] [Full Text] [Related]

  • 18. Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease.
    Xie X, Guo B, Lin X, Qin Y, Ouyang M, Li S, Zhou C.
    Angiogenesis; 2019 Nov 01; 22(4):477-479. PubMed ID: 31250326
    [Abstract] [Full Text] [Related]

  • 19. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Gadgeel SM.
    Future Oncol; 2018 Aug 01; 14(18):1875-1882. PubMed ID: 29536761
    [Abstract] [Full Text] [Related]

  • 20. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
    Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, Pérol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, Nüesch E, Balas B, Camidge DR.
    Ann Oncol; 2018 Nov 01; 29(11):2214-2222. PubMed ID: 30215676
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.